Sector practice head — Pharma & Biotech (China) · CEO

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Pharmaceuticals & Biotechnology on a senior CEO leadership mandate anchored in China. The remit explicitly spans Continental Europe, Canada, Singapore.

This is a sector or practice-head mandate combining deep domain credibility with commercial ownership of a vertical P&L or global practice line.

The mandate fits a leader comfortable owning the narrative externally while upgrading how decisions are made internally.

Context you will inherit

• Market & sector: Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities
• Geographic spine: Primary hub China with explicit corridor responsibility across Continental Europe, Canada, Singapore.
• Organisation stage: Growth agenda collides with legacy cost base; productivity and automation are board-level topics, not staff functions.
• Stakeholders: Owners may include PE operating partners, a promoter family office, or public-market investors — each with different tempo and KPIs.
• Secondary lens: R&D and innovation leadership — transitioning from generic-follow business models to differentiated, IP-rich innovation pipelines requires a different type of scientific and commercial leadership

The mandate (12–24 month arc)

1. Strategic choices: Exit or de-prioritise low-conviction bets; reallocate capital and talent to the segments with durable advantage.
2. Customer & brand: Rebuild trust in priority accounts; ensure delivery reliability and commercial discipline match the brand promise.
3. Operating tempo: Install a weekly / monthly operating rhythm that forces cross-functional decisions instead of serial escalations.
4. Risk & resilience: Partner with risk and legal so growth initiatives do not outpace control design — especially in regulated adjacencies.
5. Talent density: Recalibrate performance standards; move decisively on mis-hires in leadership roles.
6. Owner alignment: Keep PE / board / family owners aligned on timing, value creation plan, and downside scenarios.

Responsibilities (representative)

• Reset performance standards for the leadership population; act quickly on chronic underperformance.
• Align global programmes with local market reality — avoid copy-paste transformation.
• Represent the enterprise to investors, lenders, or PE partners with conservative, credible forecasts.
• Drive inclusion in succession and promotion decisions — measurable outcomes, not statements.
• Balance short-term recovery actions with investments that compound over three to five years.

Leadership profile

• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Strategic judgment: Evidence of clear portfolio choices — what to scale, fix, or exit — in Pharmaceuticals & Biotechnology.
• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Communication: Executive presence in English; additional languages valued where market-relevant.
• Geographic muscle: Comfort operating from China with regular engagement across Continental Europe, Canada.

Team & culture

The organisation runs hot — ambitious targets and thin buffers. You need to channel energy into sustainable rhythms: predictable planning, honest risk surfacing, and recovery time for teams after major pushes.

Success measures (examples)

• Growth quality: Mix of recurring revenue, new logos, and cross-sell — not volume for its own sake.
• Productivity: Unit cost, automation savings, or throughput improvements with audited baselines.
• Customer: NPS / CSAT where tracked; contract renewals; reference-ability in strategic accounts.
• Franchise: Clean compliance record; reputation stability in industry and government forums.

First 90 days (orientation arc)

• Days 1–30: Listening tour — customers, regulators (as appropriate), top team 1:1s, and unfiltered view of numbers; pause major reorganisation.
• Days 30–60: Publish a short memo on priorities, non-goals, and decision rights; align executive committee on three enterprise bets.
• Days 60–90: Lock operating cadence; fill or upgrade one to two critical seats; deliver one visible win (customer, cost, or culture).
• Commission a pragmatic view of data, cyber, and automation posture; sponsor one bounded pilot with ROI hypothesis.
• Establish escalation discipline with matrix partners — fewer meetings, clearer decision logs.

Stakeholder map (illustrative)

• Internal: CEO or regional president, CFO, risk / legal, CHRO, CIO or CDO, business GMs, internal audit.
• External: Strategic accounts, channel partners, industry associations, regulators (where material).
• Owners: PE operating partners, promoter office, or public investors — pace and clarity matter as much as vision.

Travel & mobility

Travel weighted to priority markets and quarterly global or regional forums; flexibility for crisis windows.

Compensation

Market-aligned CEO remuneration in Pharmaceuticals & Biotechnology with performance linkage; sign-on and relocation considered for exceptional fits.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Pharmaceuticals & Biotechnology and China. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: pharmaceuticals-biotech · CEO · China · Gladwin International Leadership Advisors